intro

In nature, the riparian zone is a unique rich ecosystem created through the interaction of a river with its banks. In the human body, moving blood, or hemodynamics, similarly interacts with the walls of blood vessels generating unique biological activity. This very interaction, between hemodynamics and the vascular wall, is a critical and unexplored determinant of vascular health. Riparian is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today.


Our Team

WILL ADAMS, PHD

Chief Scientific Officer, President, Founder
 

Prior to founding Riparian Pharmaceuticals, Will performed his dissertation research at Brigham and Women's Hospital and Harvard Medical School where he developed stem cell based platforms for drug discovery and personalized regenerative medicine. Will received a Ph.D. in Biomedical Engineering, a M.S. in Applied Mathematics and a B.S. in Biomedical Engineering from Harvard University. 
 


Advisory Board

GUILLERMO GARCIA-CARDENA, PHD

Founder, Scientific Advisor

Guillermo is an Associate Professor of Pathology at Harvard Medical School and the Director of the Laboratory for Systems Biology at the Center for Excellence in Vascular Biology at Brigham and Women’s Hospital in Boston. His expertise in the endothelial biology of cardiovascular diseases is widely recognized as this has been a focus of his laboratory for the past ten years. He received his Ph.D. from Yale University where he studied the molecular biology of endothelial function.

Peter Ganz, mD

Scientific Advisor

Peter is the Chief of Cardiology and the Director for the Center for Excellence in Vascular Biology at the San Francisco General Hospital and is the Maurice Eliaser Jr. Distinguished Professor of Medicine at the University of California San Francisco. He has been a pioneer and a leader in translational vascular research focusing on key elements of vascular endothelial function, inflammation and atherosclerosis. Dr. Ganz has authored over 250 publications and has served on steering committees of numerous clinical trials.